DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 450 participants.
Also called NCT05764057
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 450 participants
- Registry
-
NCT05764057 -
2022-001901-28
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT05764057. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-12 (actual); primary completion 2026-10-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
- Acronym
- DAPAPROTECTOR
- Condition
- AMI
- Condition
- STEMI
- Condition
- NSTEMI
- Condition
- Left Ventricular Dysfunction
- Intervention (Drug)
- Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)
- Intervention (Drug)
- Placebo comparator
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct05764057- Content hash
a0e18264eaa6c92877ae9c8c5ea55ad74f197dd294a9a7f8414890f19b6e0e65